Home / World Marketplace / Archive by category Global Health & Biotech (Page 27)

Archive by category Global Health & Biotech

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD CHENGDU, China and ROCKAWAY, N.J., May 02, 2025 (Korea Bizwire) – Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating treatment with KH658 [...]

Resmed Acquires VirtuOx

Acquisition supports Resmed’s growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers SAN DIEGO, May 01, 2025 (Korea Bizwire) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a [...]

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in US up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment [...]

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and manufacture biosimilar, with Sandoz to register and commercialize after expiry of relevant patents across global markets Combination therapy of ipilimumab and nivolumab used in 95% of [...]

Breaking new ground in mental health research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience launch first of its kind study investigating the day-to-day experience of patients with psychiatric disorders

Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 (Korea Bizwire) – Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric disorders, and how these experiences relate to their brain activity. The first-of-its-kind study will use novel technology to quantify brain activity, mood, and behavior at home in people who have been diagnosed [...]

ZEISS supports the transition of spatial biology to clinical research

Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation - Comprehensive solution portfolio – from multiplex immunofluorescence (mIF) staining reagents to spatial image analyses – designed to meet the challenges of clinical research - Highly controlled and fully automated operation from slide to report, with optional Laboratory Information Management System (LIMS) integration - [...]

Olon Group Strengthens Its Leadership in Bioproduction with Two Strategic Appointments in France

MILAN, April 28, 2025 (Korea Bizwire) – Olon Group, a leading global pharmaceutical CDMO, announces the appointment of Jérôme Bédier as CEO of its French entities and Andrea Conforto as M&S VP CDMO of Olon Biotech, the division dedicated to CDMO services for biologics. These appointments reinforce Olon’s strategy to expand its capabilities in Antibody-Drug Conjugates [...]

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 (Korea Bizwire) New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of Medicine Data presented included an objective response rate (ORR) of 71%, with 7% of patients achieving complete responses (CR), and a 96% disease [...]

Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase

First phase of enrollment of single device for CCM® and ICD therapy complete Marlton, NJ, April 28, 2025 (Korea Bizwire) — Impulse Dynamics® plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce that it reached an important milestone in the INTEGRA-D™ clinical trial, successfully completing [...]

EBC Financial Group Deepens Commitment to United to Beat Malaria with Renewed Global Partnership and First-Ever 5K Run Sponsorship

From strategic partnership to global employee action, EBC joins the global movement to end malaria for good WASHINGTON, April 28, 2025 (Korea Bizwire) — As the world marks World Malaria Day 2025 under the theme “Malaria Ends With Us: Reinvest, Reimagine, Reignite,” EBC Financial Group (EBC) is renewing its global partnership with the United Nations [...]